Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Fresenius
Pharma
AZ, Merck, Takeda and more get their chance to shine in Q3
AstraZeneca’s formal withdrawal of its U.S. COVID-19 vaccine application last week may best capture the changes afoot in 2022’s third quarter.
Fraiser Kansteiner
Nov 15, 2022 5:00am
Fresenius' new CEO signals 'reset' as activist investor circles
Oct 31, 2022 10:29am
Fresenius nets NBA All-Star Elliott for CKD awareness campaign
Mar 9, 2022 7:55am
CSL to buy Vifor in biopharma's largest M&A deal this year
Dec 14, 2021 9:09am
Akorn inks $74M settlement over data integrity woes
Aug 1, 2019 10:31am
Akorn’s losses narrow but clock is ticking with lenders
May 7, 2019 10:57am
